On 21 September 2011, the Committee delivered its report on the Patent Amendment (Human Genes and Biological Materials) Bill 2010. Recommending that ”the Senate should not pass the Bill”, the Committee expressed concern that the Bill could have ”a large number of unintended consequences across the entire patent system with indeterminate impacts on a range of industries and sectors”. Three Senators, all of whom had originally sponsored the Bill, disagreed with this majority decision of the Committee and released a separate dissenting report.